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Background:  Inpatient (inpt) care of congenital heart disease (CHD) can be complex, lengthy, and expensive. Major investments 
of time, financial resources, and emotional capital are very discouraging when the outcome is a fatality. We define a measure of that 
discouragement, the investment in inpt fatality (IIIF) as the resources expended in inpt care which the patient does not survive divided by all 
inpt care resources expended regardless of survival. Our purpose is to identify variations in IIIF by CHD lesion and by institutional volume.
methods:  The Pediatric Health Information System (PHIS) database representing 47 children’s hospitals was queried for admissions of 
4 CHD lesions (hypoplastic left heart syndrome (HLHS), tetralogy of Fallot (TOF), ventricular septal defect (VSD), and atrial septal defect 
(ASD)) among patients (pts) <21 years old during 2004-2013. Institutional volume, pt age, inpt deaths, billed charges (BC) and length of 
stay (LOS) were recorded. IIIF was calculated in 2 ways: (1) based on LOS and (2) based on BC.
results:  In all, 48159 admissions (11,122 HLHS, 12,891 TOF, 14,220 VSD, 9926 ASD) were identified. There were 1520 inpt deaths 
(3.2%). Mortality rates were 10.3% HLHS, 2.7% TOF, 0.7% VSD, 0.3% ASD. IIIF (BC) was 21% for HLHS, 10% TOF, 4% VSD, and 3% 
ASD. IIIF (LOS) was 16% for HLHS, 8% TOF, 4% VSD, and 3% ASD. IIIF (BC) range by institution was 0-41% for HLHS, 0-34% TOF, 
0-28% VSD, 0-45% ASD. IIIF (LOS) range by institution was 0-31% for HLHS, 0-27% TOF, 0-15% VSD, 0-26% ASD. There was no 
significant correlation of IIIF with institutional volume for any lesion.
Conclusion:  IIIF is highest in the most complex CHD, but is surprisingly high in simple lesions such as ASD and VSD, despite very low 
mortality rates. Remarkably broad variation in IIIF from one institution to another is noted in all lesions, but high IIIF is not a phenomenon 
peculiar to either low or high volume institutions. It is clear from this investigation that there is room for improvement in IIIF for CHD care in 
lesions of all complexities, at programs of all volumes. More detailed research will be required to identify specific markers for IIIF which will 
point to potentially beneficial changes to be made in CHD management.
